Search

Home > GRACEcast Lung Cancer Video > Can addition of a "heat shock protein inhibitor" to standard chemo improve outcomes in advanced NSCLC?
Podcast: GRACEcast Lung Cancer Video
Episode:

Can addition of a "heat shock protein inhibitor" to standard chemo improve outcomes in advanced NSCLC?
Category: Science & Medicine
Duration: 00:06:10
Publish Date: 2013-06-19 01:01:14
Description:

Drs. Mary Pinder, Nate Pennell, and Jack West discuss the results presented at ASCO 2013 of the GALAXY-1 trial of the HSP90 inhibitor ganetespib combined with Taxotere (docetaxel) as second line therapy for advanced NSCLC.
Total Play: 0